Announcements
- Abeona Therapeutics Provides Regulatory Update on Pz-cel
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
- Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Announces $50 Million Credit Facility
- Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
- Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
- Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
More ▼
Key statistics
On Monday, Abeona Therapeutics Inc (PCJ:DEU) closed at 3.20, 21.40% above the 52 week low of 2.64 set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.98 |
---|---|
High | 3.52 |
Low | 2.96 |
Bid | 3.14 |
Offer | -- |
Previous close | 3.10 |
Average volume | 8.29k |
---|---|
Shares outstanding | 27.36m |
Free float | 25.41m |
P/E (TTM) | -- |
Market cap | 94.10m USD |
EPS (TTM) | -2.59 USD |
Data delayed at least 15 minutes, as of Apr 29 2024.
More ▼